Ingevity NGVT Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $78.1M-9.8% | $86.6M-22.6% | $111.9M+32.7% | $84.3M-69.5% | ||
| $6.9M+6.2% | $6.5M-42.0% | $11.2M+75.0% | $6.4M+20.8% | ||
| $186M-5.1% | $195.9M-36.6% | $308.8M-7.8% | $335M+38.9% | ||
| $454.2M-7.9% | $493.2M-25.1% | $658.6M-3.6% | $683.3M-5.7% | ||
| $608.1M-5.6% | $644.1M-15.5% | $762.2M-4.6% | $798.6M+11.0% | ||
| $4.3M-97.5% | $175.2M-66.8% | $527.5M+1.7% | $518.5M+17.3% | ||
| $176.1M-36.8% | $278.8M-17.0% | $336.1M-17.0% | $404.8M+19.9% | ||
| $0-100% | $87.3M-12.0% | $99.2M-9.7% | $109.8M+211% | ||
| $1.65B-18.4% | $2.02B-22.9% | $2.62B-4.1% | $2.74B+10.8% | ||
| $92M-2.6% | $94.5M-40.3% | $158.4M-9.4% | $174.8M+39.0% | ||
| $47.1M-23.2% | $61.3M-27.4% | $84.4M+9,278% | $900K-95.4% | ||
| $341.3M+29.2% | $264.1M-27.2% | $362.9M+19.6% | $303.5M+12.9% | ||
| $1.21B-13.7% | $1.4B-4.5% | $1.47B-0.4% | $1.47B+16.1% | ||
| $1.62B-11.3% | $1.83B-8.3% | $1.99B-2.3% | $2.04B+13.5% | ||
| 300M+74,900% | 400K0.0% | 400K0.0% | 400K0.0% | ||
| $404.9M-29.2% | $572M-42.9% | $1B-0.5% | $1.01B+26.6% | ||
| $29.7M-84.8% | $195.2M-69.1% | $631.4M-9.6% | $698.3M+3.6% | ||
| $1.65B-18.4% | $2.02B-22.9% | $2.62B-4.1% | $2.74B+10.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ingevity's total assets?
- Ingevity (NGVT) holds $1.7B in total assets, down 19.7% year over year.
- How much debt does Ingevity have?
- Ingevity carries $1.4B in total debt against $38.9M of shareholders' equity, a debt-to-equity ratio of 35.13.
- How much cash does Ingevity have?
- Ingevity holds $95.4M in cash and equivalents.
- Can Ingevity cover its short-term obligations?
- Its current ratio is 1.42 — current assets exceed current liabilities.
- Where does Ingevity's balance sheet data come from?
- Every line is extracted from Ingevity's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
